135 related articles for article (PubMed ID: 21415555)
1. Postprandial serum C-peptide to plasma glucose ratio as a predictor of subsequent insulin treatment in patients with type 2 diabetes.
Saisho Y; Kou K; Tanaka K; Abe T; Kurosawa H; Shimada A; Meguro S; Kawai T; Itoh H
Endocr J; 2011; 58(4):315-22. PubMed ID: 21415555
[TBL] [Abstract][Full Text] [Related]
2. Clinical Utility of the Meal Tolerance Test in the Care of Patients with Type 2 Diabetes Mellitus.
Wakasaki H; Shono T; Nakao R; Yamamoto S; Minaga T; Fukuda S; Matsumoto R; Ohoshi T; Naka K; Nanjo K
Intern Med; 2020; 59(18):2229-2235. PubMed ID: 32938850
[TBL] [Abstract][Full Text] [Related]
3. Correlation of serum CPR to plasma glucose ratio with various indices of insulin secretion and diseases duration in type 2 diabetes.
Okuno Y; Sakaguchi K; Komada H; Hashimoto N; Hirota Y; Nakamura T; Ogawa W; Seino S
Kobe J Med Sci; 2013 Apr; 59(2):E44-53. PubMed ID: 23756662
[TBL] [Abstract][Full Text] [Related]
4. Association between beta cell function and future glycemic control in patients with type 2 diabetes.
Saisho Y; Kou K; Tanaka K; Abe T; Shimada A; Kawai T; Itoh H
Endocr J; 2013; 60(4):517-23. PubMed ID: 23268927
[TBL] [Abstract][Full Text] [Related]
5. Effect of obesity on declining beta cell function after diagnosis of type 2 diabetes: a possible link suggested by cross-sectional analysis.
Saisho Y; Tanaka K; Abe T; Shimada A; Kawai T; Itoh H
Endocr J; 2012; 59(3):187-95. PubMed ID: 22156325
[TBL] [Abstract][Full Text] [Related]
6. Postprandial serum C-peptide to plasma glucose concentration ratio correlates with oral glucose tolerance test- and glucose clamp-based disposition indexes.
Okuno Y; Komada H; Sakaguchi K; Nakamura T; Hashimoto N; Hirota Y; Ogawa W; Seino S
Metabolism; 2013 Oct; 62(10):1470-6. PubMed ID: 23831440
[TBL] [Abstract][Full Text] [Related]
7. Parameters measuring beta-cell function are only valuable in diabetic subjects with low body mass index, high blood glucose level, or long-standing diabetes.
Lee SW; Lee S; Kim SH; Kim TH; Kang BS; Yoo SH; Lee MK; Koh WJ; Kang WS; Kim HJ
Yonsei Med J; 2011 Nov; 52(6):939-47. PubMed ID: 22028157
[TBL] [Abstract][Full Text] [Related]
8. A study of serum free C-peptide responses to oral glucose load in diabetic patients: with special reference to types of diabetes and methods of treatment.
Hsieh SD; Akanuma Y; Takaku F
Tohoku J Exp Med; 1984 Mar; 142(3):249-60. PubMed ID: 6374968
[TBL] [Abstract][Full Text] [Related]
9. Postprandial serum C-peptide is a useful parameter in the prediction of successful switching to liraglutide monotherapy from complex insulin therapy in Japanese patients with type 2 diabetes.
Iwao T; Sakai K; Sata M
J Diabetes Complications; 2013; 27(1):87-91. PubMed ID: 22863615
[TBL] [Abstract][Full Text] [Related]
10. Associations between time in range and insulin secretory capacity in Japanese patients with type 2 diabetes.
Tanaka K; Okada Y; Uemura F; Tanaka Y
Sci Rep; 2024 Jun; 14(1):12910. PubMed ID: 38839813
[TBL] [Abstract][Full Text] [Related]
11. Modification of postprandial hyperglycemia with insulin lispro improves glucose control in patients with type 2 diabetes.
Feinglos MN; Thacker CH; English J; Bethel MA; Lane JD
Diabetes Care; 1997 Oct; 20(10):1539-42. PubMed ID: 9314631
[TBL] [Abstract][Full Text] [Related]
12. Pancreatic B-cell function in non-insulin-dependent diabetes mellitus during successive periods of sulfonylurea and insulin treatment: serum C-peptide response to glucagon and urine C-peptide excretion.
Hsieh SD; Iwamoto Y; Matsuda A; Kuzuya T
Endocrinol Jpn; 1987 Aug; 34(4):561-7. PubMed ID: 3315640
[TBL] [Abstract][Full Text] [Related]
13. C-peptide response to glucagon in type 2 diabetes mellitus: a comparison with oral glucose tolerance test.
Iwasaki Y; Kondo K; Hasegawa H; Oiso Y
Diabetes Res; 1994; 25(3):129-37. PubMed ID: 7671552
[TBL] [Abstract][Full Text] [Related]
14. Combination of disease duration-to-age at diagnosis and hemoglobin A1c-to-serum C-peptide reactivity ratios predicts patient response to glucose-lowering medication in type 2 diabetes: A retrospective cohort study across Japan (JDDM59).
Kanatsuka A; Sato Y; Higashi Y; Goto Y; Kawai K; Maegawa H;
J Diabetes Investig; 2021 Nov; 12(11):1967-1977. PubMed ID: 33837666
[TBL] [Abstract][Full Text] [Related]
15. Serum bilirubin concentrations are positively associated with serum C-peptide levels in patients with Type 2 diabetes.
Chung JO; Cho DH; Chung DJ; Chung MY
Diabet Med; 2014 Nov; 31(11):1316-22. PubMed ID: 24910105
[TBL] [Abstract][Full Text] [Related]
16. Postprandial serum C-peptide to plasma glucose ratio predicts future insulin therapy in Japanese patients with type 2 diabetes.
Saisho Y; Kou K; Tanaka K; Abe T; Shimada A; Kawai T; Itoh H
Acta Diabetol; 2013 Dec; 50(6):987-8. PubMed ID: 23212668
[No Abstract] [Full Text] [Related]
17. Impaired first-phase insulin response predicts postprandial blood glucose increment in patients with recently diagnosed type 2 diabetes.
Gredal C; Rosenfalck AM; Dejgaard A; Hilsted J
Scand J Clin Lab Invest; 2007; 67(3):327-36. PubMed ID: 17454847
[TBL] [Abstract][Full Text] [Related]
18. Short-term recovery of insulin secretion in response to a meal is associated with future glycemic control in type 2 diabetes patients.
Enkaku A; Chujo D; Kamigishi M; Inagawa S; Matsukoshi S; Sakai W; Takikawa A; Fujisaka S; Tobe K
J Diabetes Investig; 2024 Apr; 15(4):437-448. PubMed ID: 38151917
[TBL] [Abstract][Full Text] [Related]
19. Effect of Glycemic Control on Chylomicron Metabolism and Correlation between Postprandial Metabolism of Plasma Glucose and Chylomicron in Patients with Type 2 Diabetes Treated with Basal-bolus Insulin Therapy with or without Vildagliptin.
Okajima F; Emoto N; Kato K; Sugihara H
J Atheroscler Thromb; 2017 Feb; 24(2):157-168. PubMed ID: 27397060
[TBL] [Abstract][Full Text] [Related]
20. Impact of insulin sensitivity, beta-cell function and glycaemic control on initiation of second-line glucose-lowering treatment in newly diagnosed type 2 diabetes.
Rathmann W; Strassburger K; Bongaerts B; Bobrov P; Kuss O; Müssig K; Markgraf DF; Szendroedi J; Herder C; Roden M;
Diabetes Obes Metab; 2017 Jun; 19(6):866-873. PubMed ID: 28127851
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
